Manufacturers associated with the EpiPen device have drawn heavy criticism from consumers and lawmakers, but it's not the only lifesaving drug on the market experiencing soaring costs. Insulin prices have risen to nearly $400 a month in some cases, roughly…
Supply Chain
Mylan's life-saving EpiPen injection device is not the only medication in the company's portfolio that has seen large price spikes, reports NBC News.
Senator Joe Manchin's (D-W.Va.) ties to the congressional scrutiny surrounding the skyrocketing price of EpiPens runs deeper than just politics. His daughter, Heather Bresch, is CEO of Mylan, the company behind the epinephrine injection, reports The Washington Post.
Getting your master's degree in global sourcing
The Food and Drug Administration reached an agreement with representatives of the medical device industry for proposed recommendations of the medical device user fee program.
Advertisement
In June, the CDC recommended against using AstraZeneca's nasal flu vaccine, FluMist, citing a lack of evidence regarding the vaccine's efficacy. FluMist's absence from the American market is causing some physicians to worry about a potential flu vaccine shortage.
The Food and Drug Administration submitted an annual report to Congress regarding the use of citizen petitions that allow the general public to ask the agency to refrain from approving a generic drug or biosimilar over potential health concerns, reported…
Senator Bernie Sanders (D-Vt.) responded to news of Pfizer's $14 billion acquisition of Medivation by calling on the drug industry to lower the cost of prescription drugs, reported CNN.
The Food and Drug Administration granted de novo clearance for ImPACT, a device used to assess cognitive function following possible concussion or brain injury.
International investors are increasingly bidding for biomedical laboratories in Boston in what they see as an opportunity to profit from increasing property values and rent, according to The Boston Globe.